Oncology & Cancer

Gilteritinib superior in relapsed, refractory FLT3-mutated AML

(HealthDay)—For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer ...

Inflammatory disorders

The diet-microbiome connection in inflammatory bowel disease

Much remains mysterious about the factors influencing human inflammatory bowel disease (IBD), but one aspect that has emerged as a key contributor is the gut microbiome, the collection of microorganisms dwelling in the intestines.

Medications

Rituximab noninferior to cyclosporine in membranous nephropathy

(HealthDay)—In patients with membranous nephropathy at high risk for progressive disease, rituximab is noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and is superior in ...

Oncology & Cancer

Q&A: PET scans important in assessing some forms of lymphoma

Dear Mayo Clinic: My father just started chemotherapy for lymphoma, and he is scheduled for a positron emission tomography or PET scan after his first three treatments. How do doctors decide when to perform a PET scan, and ...

page 2 from 16